U.S. markets close in 5 hours 9 minutes

Blueprint Medicines Corporation (BPMC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
102.42-0.05 (-0.05%)
As of 10:50AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close102.47
Open102.86
Bid102.36 x 900
Ask102.74 x 800
Day's Range101.82 - 103.84
52 Week Range43.29 - 105.50
Volume33,527
Avg. Volume422,427
Market Cap5.661B
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-7.70
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est102.57
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire

    Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on October 1, 2020, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 77,118 shares of its common stock and an aggregate of 38,557 restricted stock units (RSUs) to five new employees, including a grant of non-qualified stock options to purchase 65,000 shares of common stock and 32,500 RSUs to Fouad Namouni, M.D., the company's recently appointed President, Research & Development , under Blueprint Medicines' 2020 Inducement Plan.

  • Imagine Holding Blueprint Medicines (NASDAQ:BPMC) Shares While The Price Zoomed 333% Higher
    Simply Wall St.

    Imagine Holding Blueprint Medicines (NASDAQ:BPMC) Shares While The Price Zoomed 333% Higher

    Buying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...

  • Blueprint Medicines Rises YTD on Robust Ayvakit Progress
    Zacks

    Blueprint Medicines Rises YTD on Robust Ayvakit Progress

    Blueprint Medicines' (BPMC) lead drug Ayvakyt/Ayvakit approved for PDGFRA Exon 18 mutant GIST is off to a solid start. The company's efforts to expand the drug's label are promising as well.